The market frenzy in December over the potential rescheduling of marijuana from a Schedule I to a Schedule III substance sent cannabis stocks soaring. However, the reality is that not all companies will benefit equally from this shift. The primary windfall is expected to flow to Multi-State Operators (MSOs) currently selling cannabis products across the United States. Among these, Green Thumb Industries (GTBIF) stands out as a particularly compelling candidate.
Why Green Thumb? What sets this cannabis stock apart?
The most significant victory for MSOs from rescheduling lies in a drastic reduction in tax burden. The key is the anticipated end of Section 280E of the U.S. tax code. This provision has historically blocked cannabis companies from taking standard business deductions, forcing them to pay taxes based on gross profit rather than operating income.
Once this restriction is lifted, profitability and free cash flow for MSOs are poised to improve dramatically. In a recent interview, Green Thumb’s CEO estimated that rescheduling would generate an additional $60 million in annual free cash flow for the company. He noted that the change would allow the business to be taxed on operating income, freeing up substantial capital to pursue growth initiatives and expand operations.
Notably, Green Thumb is already considered one of the safer investments in the cannabis space. The company is not only consistently generating positive cash flow but is also profitable on a net income basis. Over the past 12 months, it has delivered $154.5 million in free cash flow and $43.6 million in net income, on revenue of nearly $1.2 billion.
As a leading U.S. cannabis company, Green Thumb’s current market capitalization of approximately $1.9 billion appears relatively modest, with a Price-to-Sales ratio of just 1.7. For a company with significant growth potential—especially if further cannabis reform unfolds—this valuation could present an attractive entry point.
Of course, the cannabis sector remains fraught with risk and uncertainty, and the rescheduling process is not yet officially complete. However, for investors willing to be patient and take a long-term view, Green Thumb presents a compelling case. Its direct path to enhanced profitability from the policy shift, proven financial strength, and reasonable valuation suggest significant upside potential over time. This policy-driven cash flow transformation positions Green Thumb as one of the clearest beneficiaries on the horizon.
